Related Articles
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature
Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)
Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer (Review)